All In Biotech

Drug Trial Radar · NCT00396227

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

A Multi-center, Randomized, Open-label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment With Vildagliptin 100 mg, qd to Thiazolidinedione (TZD) as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy in a Community-based Practice Setting.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,665 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,665

Actual

Start

Oct 2006

Primary completion

Oct 2007

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years

Summary

As written by the sponsor on the registry.

This study is designed to evaluate, in a primary care setting, the safety and efficacy of vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients with type 2 diabetes inadequately controlled by metformin alone.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • vildagliptinDrug

    vildagliptin as add-on to metformin

  • thiazolidinedione (TZD)Drug

    TZD add-on to metformin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in HemoglobinA1c (HbA1c)Time frame: after 12 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Pharmaceuticals

    East Hanover, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.